Skip to main content

Government officials will never ask you to transfer money or disclose bank log-in details over a phone call.

Call the 24/7 ScamShield Helpline at 1799 if you are unsure if something is a scam.

Agency for Care Effectiveness
  1. Home
  2. Healthcare professionals
  3. ACE Technology Guidances
  4. Drug Guidance
  5. Epcoritamab for relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy
Drug guidance

Epcoritamab for relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy

Condition

Blood and Immune System

Cancer

16 September 2025

-

Published on 4 Jun 2025
Last Updated on 16 Sep 2025

Guidance Recommendations

The Ministry of Health’s Drug Advisory Committee has not recommended epcoritamab for inclusion on the MOH List of Subsidised Drugs for treating relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. The decision for epcoritamab was based on the uncertainties surrounding its magnitude of clinical benefit, unfavourable cost-effectiveness compared with chemotherapy, and the unacceptable price-volume agreement proposed by the company.

Clinical indication, subsidy class and MediShield Life claim limit for epcoritamab are provided in the Annex.

Epcoritamab for relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy (Updated 16 Sep 2025) [PDF, 249 KB]

PES_Epcoritamab for previously treated relapsed or refractory diffuse large B-cell lymphoma (Updated 16 Sep 2025) [PDF, 109 KB]

Back to top